SCHEMBL3049285

SCHEMBL3049285

COc1cc2c(cc1S(N)(=O)=O)CCN(S(=O)(=O)c1cccc(Cl)c1)C2=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 1/20 0.44
HPGD P15428 2/20 0.43
NPSR1 Q6W5P4 1/20 0.43
KMT2A Q03164 4/20 0.42
ALDH1A1 P00352 3/20 0.42
PDE4A P27815 1/20 0.42
PDE4B Q07343 1/20 0.42
PDE4C Q08493 1/20 0.42
PDE4D Q08499 1/20 0.42
KCNA3 P22001 1/20 0.40
HTR6 P50406 2/20 0.39
CYP3A4 P08684 1/20 0.39
MEN1 O00255 3/20 0.39
KDM4E B2RXH2 1/20 0.38
POLB P06746 1/20 0.38
RAB9A P51151 1/20 0.38
KDM2B Q8NHM5 1/20 0.38
CA2 P00918 1/20 0.38
CA9 Q16790 1/20 0.38
PTGES2 Q9H7Z7 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3059107 0.89 CYP11B1 (0.48) KMT2APDE4APDE4BPDE4CPDE4D
SCHEMBL3051277 0.89 MMP2 (0.46) MMP2HPGDNPSR1KMT2AALDH1A1
SCHEMBL3051781 0.83 PKM (0.48) MMP2KMT2APDE4APDE4BPDE4C
SCHEMBL3051374 0.83 PTGDR2 (0.41) KMT2AALDH1A1PDE4APDE4BPDE4C
SCHEMBL3052392 0.82 TSHR (0.47) KMT2APDE4APDE4BPDE4CPDE4D
SCHEMBL3042255 0.80 CHRNA7 (0.48) HPGDNPSR1PDE4APDE4BPDE4C
SCHEMBL3062438 0.80 AKR1C3 (0.59) NPSR1KMT2AALDH1A1PDE4BPDE4D
SCHEMBL3052679 0.77 CYP11B1 (0.51) MMP2KMT2AALDH1A1PDE4APDE4B
SCHEMBL3153291 0.73 GRM5 (0.52) KMT2AALDH1A1MEN1KDM4ECA2
SCHEMBL3050420 0.73 MMP1 (0.44) MMP2ALDH1A1PDE4APDE4BPDE4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100222299-A1 COMPOUND STERIX LIMITED (GB) 2010-09-02 US claimed
EP-2155192-B1 TETRAHYDROISOQUINOLINES AS TUMOUR GROWTH INHIBITORS STERIX LTD (GB) 2016-09-28 EP disclosed
US-8394825-B2 Compound STERIX LIMITED (GB) 2013-03-12 US disclosed
US-20100222299-A1 COMPOUND STERIX LIMITED (GB) 2010-09-02 US disclosed
EP-2155192-A2 TETRAHYDROISOQUINOLINES AS TUMOUR GROWTH INHIBITORS Sterix Limited (GB) 2010-02-24 EP disclosed
WO-2008117061-A2 TETRAHYDROISOQUINOLINES AS TUMOUR GROWTH INHIBITORS STERIX LIMITED (GB) 2008-10-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100222299-A1 COMPOUND MKI67, VHL, MYC MMP2 292/4885HPGD 694/4885NPSR1 2125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.